basic helix-loop-helix family member e22Genealiases: BHLHB5 · Beta3 · Beta3a · CAGL85 · TNRC20
Q-omics provides the consensus-scored BHLHE22 profile across patient tissues and cancer cell-line models. BHLHE22 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BHLHE22 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, BHLHE22 RNA expression shows 16,948 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KICH, and LSCC as cancer lineages where BHLHE22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BHLHE22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BHLHE22 survival associations across molecular data types. BHLHE22 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BHLHE22 RNA expression–survival associations across cancer types. High BHLHE22 expression shows unfavorable associations in KIRP, but favorable associations in HNSC, SKCM, UCEC, LUAD and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BHLHE22 RNA expression.
This table summarizes BHLHE22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for BHLHE22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BHLHE22 shows lower tumor expression in KICH, BLCA, BRCA, THCA and LUSC and higher tumor expression in LUAD. The KICH box plot shows higher BHLHE22 RNA expression in normal versus tumor tissue (log2 FC = −0.385, t-test p < 0.001).
This table shows molecular features associated with BHLHE22 in patient tissues and cancer cell lines. In patient samples, BHLHE22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BHLHE22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
